Redefining Imaging Workflows in Clinical Trials
At the Veeva R&D and Quality Summit in Boston, Moe Alsumidaie interviewed Jeff Sorenson, CEO of Yunu, and Steve...
Moe Alsumidaie
What Research Sites Say They Need from Sponsors
At Veeva’s 2025 R&D & Quality Summit, site leaders described how brittle identity systems, sprawling vendor networks, and poorly...
How ICH E20 is Redefining Adaptive Clinical Trials
In the third month of a multi-arm trial for an aggressive brain cancer, the sponsor found itself facing a...
Pharma’s Next Opportunity: AI and Standardization
At Veeva R&D and Quality Summit in Boston, the pain points of managing complex processes and entering data manually...
ICH E6(R3) Raises the Bar on Imaging in Clinical Trials—Are You Ready?
When the FDA inspector arrived, no one expected imaging to be the issue. The scans had been read. The...
What Clinical Trial Venture Capital Think About Clinical Trial Tech
“Even when the ROI is 10 to 13x, it still takes six years to adopt.” That’s the paradox that...
Pharma Cuts Clinical Trial CSR Time by >50% With AI
AI is revolutionizing clinical documentation in clinical trials. In this interview, Anita Modi, CEO and Founder of Peer AI,...
Veeva and IQVIA: A New Era of Collaboration in Clinical Trials
In a transformative move, Veeva Systems and IQVIA, two titans in the life sciences sector, have shifted from litigation...
Why FDA’s Draft 510(k) Guidance is Forcing Sponsors to Rethink Device Submissions
The device team thought they were following the playbook. They chose a predicate that had been cleared two decades...
How Sponsors Can Win or Lose in the 510(k) Strategy Pathway
The start-up team was confident. Their Class II device had promising bench data, strong engineering, and investors eager for...